ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,983.99
-0.29%
Dow Jones
43,910.98
-0.86%
US Dollar vs MXN
20.5917
1.17%
Brent Oil
71.62
-0.29%
Bitcoin
88,080.96
-0.75%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX

  6. abrdn Australia Equity Fund Inc (IAF) Cotización

abrdn Australia Equity Fund Inc

abrdn Australia Equity Fund Inc (IAF)

iShares
4.51
-0.04
(-0.88%)
Al cierre: 12 Noviembre 3:00PM
Delayed by 15 minutes
4.52
0.01
( 0.22% )
Fuera de horario: 4:38PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
4.52
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
94,976
4.49 Rango del Día 4.5758
3.7471 Rango de 52 semanas 4.75
Capitalización de Mercado [m]
115.121M
Precio Anterior
4.55
Precio de Apertura
4.55
Hora
386
@
4.51
Última hora de negociación
17:30:00
Volumen financiero
US$ 430,330
Precio Promedio Ponderado
4.5309
Volumen promedio (3 m)
61,609
Acciones en circulación
25,469,348
Rendimiento del Dividendo
10.62%
Ratio Precio/Utilidad
73.17
Beneficio por acción (BPA)
0.06
turnover
5.18M
Beneficio neto
1.57M

Acerca de abrdn Australia Equity Fund Inc

The Funds principal investment objective is longterm capital appreciation through investment primarily in equity securities of Australian companies listed on the Australian Stock Exchange Limited ASX. The Funds secondary investment objective is current income. The Funds principal investment objective is longterm capital appreciation through investment primarily in equity securities of Australian companies listed on the Australian Stock Exchange Limited ASX. The Funds secondary investment objective is current income.

Sector
Unit Inv Tr, Closed-end Mgmt
Industria
Unit Inv Tr, Closed-end Mgmt
Sitio web
www.abrdniaf.com
Sede
Baltimore, Maryland, USA
Fundado
-
abrdn Australia Equity Fund Inc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the American Stock Exchange with ticker IAF. The last closing price for abrdn Australia Equity was US$4.55. Over the last year, abrdn Australia Equity shares have traded in a share price range of US$ 3.7471 to US$ 4.75.

abrdn Australia Equity currently has 25,469,348 shares in issue. The market capitalisation of abrdn Australia Equity is US$115.89 million. abrdn Australia Equity has a price to earnings ratio (PE ratio) of 73.17.

IAF Últimas noticias

Más noticias

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

26 Septiembre 2024
Edgar (US Regulatory)

Form 40-17G - Fidelity Bond [Rule 17G-1(g)]

15 Agosto 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

06 Agosto 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Julio 2024
Edgar (US Regulatory)

Form N-CSRS - Certified Shareholder Report, Semi-Annual

08 Julio 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

18 Junio 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

23 Mayo 2024
Edgar (US Regulatory)

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

08 Febrero 2024
Edgar (US Regulatory)

Form N-CEN - Annual Report for Registered Investment Companies

16 Enero 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

12 Enero 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.071.573033707874.454.59884.42570134.52468907CS
4-0.1-2.16450216454.624.624.34663854.50576677CS
12-0.01-0.2207505518764.534.754.31616094.54769009CS
260.153.432494279184.374.754.08501564.46295439CS
520.7419.57671957673.784.753.7471655634.28900866CS
156-1.76-28.0254777076.286.393.6618664.68846266CS
260-0.72-13.74045801535.246.662.99641794.98945587CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
GNSGenius Group Limited
US$ 1.32
(25.71%)
3.8M
KAPAKairos Pharma Ltd
US$ 2.49
(21.21%)
342.12k
MRTMarti Technologies Inc
US$ 2.0488
(6.71%)
209
MDYGSPDR S&P 400 Mid Cap Growth
US$ 97.63
(5.91%)
1.39k
ASMAvino Silver and Gold Mines Ltd
US$ 1.14
(5.56%)
43.15k
EFSH1847 Holdings LLC
US$ 0.76
(-28.97%)
2.22M
SLNDSouthland Holdings Inc
US$ 2.59
(-19.31%)
15.89k
YCBDcbdMD Inc
US$ 0.455
(-8.63%)
925.88k
XTNTXtant Medical Holdings Inc
US$ 0.494
(-8.52%)
12.79k
RHERegional Health Properties Inc
US$ 1.50
(-8.46%)
1.54k
FXIiShares China Large Cap
US$ 30.28
(-0.10%)
18.21M
SPYSPDR S&P 500
US$ 596.17
(-0.12%)
9.16M
LQDiShares iBoxx Dollar Investment Grade Corporate Bond
US$ 108.65
(0.00%)
6.26M
XLFFinancial Select Sector
US$ 49.74
(0.00%)
5.31M
JAVAJP Morgan Active Value ETF
US$ 66.85
(0.00%)
5.1M

Discusión

Ver feed completo
The_Gman The_Gman 2 minutos hace
Space. The difference between witnessing a kid napping....and a kidnapping.

Yeah, that's where the pic came from.
NB
ignatiusrielly35 ignatiusrielly35 2 minutos hace
You have no information as to when specifically the ATM is used. Period. In fact, I recall you attributing a price dip earlier this year to dilution in one quarter and the 10q showed virtually none. I repeat, blind guess.
AVXL
12yearplan 12yearplan 3 minutos hace
Sorry for the late reply; .. from your two links and thanks..
 
Summary.
 
Since the early 1970s, hourly inflation-adjusted wages received by the typical worker have barely risen, growing only 0.2% per year. Assigning relative responsibility to the policies and economic f
navycmdr navycmdr 3 minutos hace
https://x.com/InvestIt3/status/1856406733754708460
FNMA
2B_unknown 2B_unknown 3 minutos hace
Yes, we have had the golden ticket for some time now:)

We got this thing, just a matter of time.
NWBO
Hosai Hosai 3 minutos hace
From what I can see based on historical EMA review start dates in late 22 and 23 and aided by chat GPT it guesses the last 2 EMA review start dates for 2024 will be Nov 28th and Dec 27th.
If Anavex were to be aiming for the Nov 28th (ish) it would need to submit any time now. Obv though even
AVXL
MartinLutherKing MartinLutherKing 3 minutos hace
It just hit the wires brother
https://www.forbes.com/sites/jessicaourisman/2024/11/12/the-firsthand-results-of-a-nanofat-treatment-using-stem-cells-and-prp/
ELAB
manibiotech manibiotech 3 minutos hace
Yep nothing for market to be in any FOMO mode 
Likely will slowly go down over next few days without news . As I also said after ASM
ASM
Groveman1 Groveman1 4 minutos hace
Lucky, There's a new response on StockRunners twitter site today 11/12/24 on LLBO. Please check it and see if you can understand what this means for LLBO. StockRunners talks about attorneys and filing papers, but seems to be speaking about the other Company attached to the Post. Check it out.
LLBO
FeMike FeMike 4 minutos hace
I think they would rather say the inspection is completed even if the 10-q is up to September 30 only. If it's done by now since the q was prepared this nov. Therefore, it is not completed up to now.

My personal opinion is that saying "the inspections have been completed" is a bit too
NWBO
cottonisking cottonisking 4 minutos hace
No, peanuts and small money, compared to this board waiting here since 2008 and going through United States' Presidents and nut cases. Shut this mental ward down now. These guys have nothing better to do. Most must be in their 80s.
LEHNQ
northam43 northam43 4 minutos hace
Report #2 October 2024 SPX Cycles

https://investorshub.advfn.com/uimage/uploads/2024/11/12/inz[o2_Completed_Cycles.PNG
manibiotech manibiotech 5 minutos hace
Look at section subsequent events in 10 q

Hmm
NWBO
jimr1717 jimr1717 5 minutos hace
New Tesla Involved in a Crash While on FSD, the Teslacam Footage Was All Police Needed
3 Nov 2024, 22:00 UTC •

Bob claims that the moment the pickup truck slammed into his rear end, the FSD turned the steering wheel to the left to prevent his Tesla from hitting the vehicle wait
TSLA
MRJ25 MRJ25 5 minutos hace
Reddit will be better.
FNMA
Rebel13 Rebel13 6 minutos hace
There’s a saying about not being able to find your a$$ even if handed to you. Didn’t realize you were real!
ELTP
art2426 art2426 6 minutos hace
We're not getting into politics? Really? Who exactly brought THIS up? ---- "Especially with the new pro small business President we just elected!"


How is reading this board, NOT FUN?
BIEL
jimr1717 jimr1717 6 minutos hace
How? Watch and learn.
TSLA
mrwrn2010 mrwrn2010 7 minutos hace
Blast from the past!
ELTP
Mactheriverrat Mactheriverrat 7 minutos hace
Thoughts on TLRY?
TLRY
exwannabe exwannabe 7 minutos hace
Reimbursement. The Company has evaluated and selected specialized, highly experienced consultants with whom to undertake preparations for a potential reimbursement review ...
In other words, not even close to submitting the evidence that kicks off the NICE process.
NWBO
gdog gdog 8 minutos hace
11-12 buy/cover EVH $14.19 + 4.15%
MahinAgency MahinAgency 8 minutos hace
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
CRDL
againstallodds againstallodds 8 minutos hace
Market expects gold delivery, imagine if no delivery

No gold = no created value
NBRI
CommodityCoverage CommodityCoverage 8 minutos hace
Developing therapeutic compounds for pediatric diseases with unmet medical needs and a large addressable market, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v), recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical cond
TTI

Su Consulta Reciente

AMEX
IAF
abrdn Australia Equity
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados